Menu

BeyondSPX has rebranded as EveryTicker. We now operate at everyticker.com, reflecting our coverage across nearly all U.S. tickers. BeyondSPX has rebranded as EveryTicker.

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (3734)

Company Market Cap Price
ALLR Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
$19.45M
$1.22
-1.61%
PIII P3 Health Partners Inc.
Healthcare Services & Facilities
$18.73M
$2.65
+6.00%
TLPH Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
$18.71M
$0.91
-2.03%
IRIX IRIDEX Corporation
IRIDEX directly designs, manufactures and sells ophthalmology devices (laser platforms, delivery systems) for eye diseases.
$18.22M
$1.05
+0.96%
ANEB Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
$18.08M
$0.37
-17.91%
CTXR Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
$17.82M
$0.87
+1.23%
DQWS DSwiss, Inc.
DQWS provides turnkey OEM/ODM contract manufacturing services for health care, beauty, and nutraceutical products.
$17.48M
$0.08
EVOK Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
$17.07M
$10.98
+0.32%
LESL Leslie's, Inc.
AccuBlue water-testing systems and related diagnostic testing capabilities are direct testing instruments offered to customers.
$16.91M
$1.83
+0.82%
NAII Natural Alternatives International, Inc.
Direct contract manufacturing services for private-label vitamins, minerals, herbal and other health care products.
$16.46M
$2.71
+0.74%
SER Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
$16.09M
$1.50
-4.78%
KNW Know Labs, Inc.
Core product: KnowU CGM wearable and glucose monitoring device.
$16.05M
$2.14
ZJYL Jin Medical International Ltd.
The company designs, manufactures, and sells rehabilitation medical devices and biometrics-oriented equipment.
$15.65M
$2.15
+6.97%
PFHO Pacific Health Care Organization, Inc.
PFHO provides workers' compensation cost containment services, including healthcare provider network access and case management, within the healthcare services ecosystem.
$15.36M
$1.07
APLM Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
$15.34M
$13.81
-3.19%
BIOE Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
$15.20M
$0.40
ADGM Adagio Medical Holdings, Inc.
ADGM is a medical technology company whose core offerings are medical devices/biometrics for cardiac ablation.
$15.15M
$1.00
+1.77%
OTLC Oncotelic Therapeutics, Inc.
Oncotelic's core oncology program OT-101 and nanoparticle platform place it squarely in oncology-focused biotech.
$15.13M
$0.04
JUNS Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
$15.05M
$0.43
+7.70%
SEED Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
$14.92M
$1.28
+1.18%
APLT Applied Therapeutics, Inc.
Applied Therapeutics is a biotech focused on rare diseases, with lead programs in rare metabolic/neurologic conditions (e.g., govorestat for CMT-SORD) and out-licensing efforts in rare disease assets.
$14.83M
$0.11
+4.37%
ADAP Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
$14.58M
$0.06
+2.91%
CODX Co-Diagnostics, Inc.
Co-Dx PCR Pro instrument is a diagnostic equipment product directly manufactured by the company.
$14.43M
$0.35
-6.19%
NXPL NextPlat Corp
Management is pivoting toward higher-margin healthcare services and 340B contracts, a Healthcare Services & Facilities focus.
$14.31M
$5.14
-6.03%
COSM Cosmos Health Inc.
Owns/operates in-house EU GMP manufacturing via Cana Laboratories Holdings Cyprus Ltd. and Cana S.A., enabling contract manufacturing revenue.
$14.19M
$0.40
-0.69%
GNTA Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
$13.98M
$0.71
-1.33%
PHIO Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
$13.89M
$1.30
+2.76%
TPST Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
$13.81M
$3.15
-0.16%
LPCN Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
$13.49M
$2.42
-5.27%
CFOO China Foods Holdings Ltd.
The company provides customized wellness consultation programs and related services.
$13.45M
$0.66
GBCS Selectis Health, Inc.
Operational healthcare facilities providing in-patient care aligns with Hospital Services as a proxy for healthcare facility operations.
$13.44M
$4.40
HOTH Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
$13.39M
$1.00
-3.37%
TRIB Trinity Biotech plc
Directly manufactures glucose monitoring hardware (CGM) and wearable biosensors with an accompanying data platform.
$13.39M
$0.73
+4.99%
BIAF bioAffinity Technologies, Inc.
CyPath Lung testing is delivered as a laboratory testing service via Precision Pathology Laboratory Services (PPLS).
$12.87M
$2.83
+2.54%
← Previous
1 ... 30 31 32 33 34 ... 38
Next →
Showing page 32 of 38 (3734 total stocks)

Loading company comparison...

Loading research report...

COSM Cosmos Health Inc.

Cosmos Health Unveils Cur18, a High‑Bioavailability Curcumin Supplement Set for U.S. Launch

Apr 18, 2026
OTLC Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Reports $249 Million Net Income for FY 2025, Driven by Non‑Cash JV Valuation Gain

Apr 16, 2026
COSM Cosmos Health Inc.

Cosmos Health Reports Record Full‑Year 2025 Results, Margin Expansion and New Digital‑Asset Treasury Strategy

Apr 15, 2026
COSM Cosmos Health Inc.

Cosmos Health Secures Third Consecutive Pharmalink Order, Advancing GCC Milestone

Apr 13, 2026
COSM Cosmos Health Inc.

Cosmos Health to Launch Liv18 Liver‑Health Supplement in U.S. Market

Apr 09, 2026
IRIX IRIDEX Corporation

Iridex Expands Retina Laser Reach Through New Partnership with EyeProGPO

Apr 09, 2026
ZJYL Jin Medical International Ltd.

Jin Medical International Regains Nasdaq Minimum Bid Price Compliance After 1‑for‑20 Reverse Split

Apr 07, 2026
APLM Apollomics, Inc.

Apollomics Secures $2 Million Convertible Note to Support Clinical Development

Apr 02, 2026
LPCN Lipocine Inc.

Lipocine Inc. Reports Phase 3 Failure of LPCN 1154 for Postpartum Depression

Apr 02, 2026
BIAF bioAffinity Technologies, Inc.

bioAffinity Technologies Reports 146% YoY Growth in CyPath® Lung Test Unit Sales for Q1 2026

Apr 01, 2026
COSM Cosmos Health Inc.

Cosmos Health Announces EN 12791 Certification for C‑Scrub Wash 4% Surgical Hand Disinfectant

Apr 01, 2026
ALLR Allarity Therapeutics, Inc.

Allarity Therapeutics Reports 2025 Financial Results, Highlights Progress on Stenoparib Program

Mar 31, 2026
GNTA Genenta Science S.p.A.

Genenta Science (Evolving into Saentra Forge) Announces Binding Offer to Acquire Controlling Stake in Sòphia High Tech

Mar 27, 2026
IRIX IRIDEX Corporation

Iridex Reports First‑Time Positive Adjusted EBITDA in Q4 2025, Revenue Misses Consensus

Mar 27, 2026
OTLC Oncotelic Therapeutics, Inc.

Oncotelic’s Subsidiary Sapu Nano to Showcase Deciparticle Nanomedicine Platform at BIO‑Europe Spring 2026

Mar 24, 2026
TRIB Trinity Biotech plc

Trinity Biotech Announces 85% Accuracy for New Prostate Cancer Liquid Biopsy Test

Mar 23, 2026